Some previously known target–disease associations detected were IFNAR2 for CML, IFNAR2 for multiple myeloma, SIRT1 for type II diabetes mellitus (T2DM), TP53 for colorectal cancer, PPARG for T2DM and IL10 for both Crohn’s disease and inflammatory bowel disease. Here, IFNAR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.